Xencor (XNCR) Doses First Patient in Phase 1b Trial of Subcutaneous Formulation of XmAb7195

September 15, 2016 8:06 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been dosed in a Phase 1b multi-dose trial of subcutaneously administered XmAb®7195, a potential treatment for allergic disease.

"A previously completed Phase 1a study of intravenous administration of XmAb7195 has shown potent suppression of IgE, in particular demonstrating the rapid clearance of IgE from the circulation, while being generally well tolerated by patients," said Paul Foster, M.D., chief medical officer at Xencor. "We expect to report interim data from this Phase 1b subcutaneous trial in 2017."

Complete data results from a Phase 1a, first-in-human study for IV administration of XmAb7195 were presented at the American Thoracic Society (ATS) 2016 International Conference in May 2016. Data showed that IV XmAb7195 was generally well tolerated with transient, asymptomatic thrombocytopenia reported at doses ≥2.0 mg/kg, and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects.

The poster is available on the Events and Presentations page of Xencor's website under "Archived Scientific Presentations" at http://investors.xencor.com/events.cfm.

For more information about this Phase 1b subcutaneous XmAb7195 clinical trial please visit to www.clinicaltrials.gov (identifier: NCT02881853).

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Add Your Comment